RBC reiterates Gilead at outperform

Gilead Sciences Inc. was reiterated by RBC Capital Markets analyst Jason Kantor at outperform, average risk, and an increased price target of $78 from $73. RBC raised its third-quarter earnings per share estimate to $0.56 from $0.54 based on better-than-expected performance of Atripla and Truvada. IMS script data support the view that Atripla is accelerating the growth of the combined Atripla/Truvada franchise, according to the analyst. Kantor raised 2007 GAAP earnings per share estimates to $2.68 from $2.46 on strength of the core HIV franchise. Shares of the Foster City, Calif.-based biopharmaceutical company were up 55 cents, or 0.82%, at $67.33. (Nasdaq: GILD)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.